LONDON, UNITED KINGDOM--(Marketwired - Mar 3, 2016) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), a producer of the highly bioavailable Phytofare® catechin complex, today announced that it has relocated its sales offices to London, England, to better accommodate the growing demand for product and maintain a strategic position that accommodates operations in Europe, North America and South Africa. Previously, all sales were handled from the Company's offices in South Africa.

Callum Cottrell-Duffield, Vice President of Sales and Marketing for Plandaí Biotechnology, stated, "Since launching Phytofare® late 2015, our sales have steadily grown. Our first customers were, naturally, close to home in South Africa, but in recent months our efforts in Western Europe have begun to translate into growing sales abroad. Several products containing Phytofare® are now available throughout the continent and all indications are that this momentum will continue building, which creates several logistical problems as South Africa is several time zones and thousands of miles removed from our customer base. Locating our main sales offices in London allows Plandaí to better service customers and respond to inquiries in a timely manner. Further, where we have operations in the U.S. and South Africa, basing operations in London permits us better access from a time-zone standpoint, and travel, of course, is also significantly easier."

Mr. Cottrell-Duffield reiterated that the company will continue to maintain operations in South Africa, from where it will manage in-country sales and manufacturing. However, in establishing the Company's corporate and sales offices in the heart of London's financial district, Plandaí can consolidate various protocols such as corporate compliance and record keeping. The Company will keep a presence in the United States to develop local customers and manage the legal aspects of remaining a US-listed company, including accounting and financial reporting.

Plandaí also announced that it has accepted the resignation of Jamen Shively from the Board of Directors effective February 29, 2016. Mr. Shively has served as a director since February 2014. Mr. Shively cited his heavy travel schedule and outside business pursuits in resigning. Mr. Roger Baylis-Duffield, Chairman of the Board of Directors, commented, "We are grateful for the guidance and expertise Jamen brought to Plandaí and wish him the best of success in his future efforts."

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at

Contact Information:

Hannah Merrill
(917) 900-6829